SEC Form 4 · accession 0001062993-16-011291
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Wegman
Officer — President · Director · 10% Owner
Period of report
Aug 23, 2016
Accepted (ET)
Aug 24, 2016 · 7:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Aug 23, 2016 | S | 4,100 | $38.6048 | D | 191,722 | D | |
| Common Stock, $0.001 par valueF2 | Aug 24, 2016 | S | 4,173 | $38.0773 | D | 187,549 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $38.6048 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $38.13 to $39.11. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $38.0773 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $38.00 to $38.25. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.